FDA approval summary: sunitinib for the treatment of progressive well-differentiated locally advanced or metastatic pancreatic neuroendocrine tumors. - Wikidata - awgldk - TriplyDB

FDA approval summary: sunitinib for the treatment of progressive well-differentiated locally advanced or metastatic pancreatic neuroendocrine tumors.

FDA approval summary: sunitinib for the treatment of progressive well-differentiated locally advanced or metastatic pancreatic neuroendocrine tumors.

http://www.wikidata.org/entity/Q36182844

about

Sunitinib: the antiangiogenic effects and beyond Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma.Integration of drug, protein, and gene delivery systems with regenerative medicine.Multitarget inhibitors derived from crosstalk mechanism involving VEGFR2.Targeted therapies in neuroendocrine tumors (NET): clinical trial challenges and lessons learned The use of targeted therapies in pancreatic neuroendocrine tumours: patient assessment, treatment administration, and management of adverse events.A woman with metastatic pancreatic neuroendocrine tumor.Current understanding of the molecular biology of pancreatic neuroendocrine tumors.Pancreatic NETs: where do we stand now?Sex-Divergent Clinical Outcomes and Precision Medicine: An Important New Role for Institutional Review Boards and Research Ethics Committees.Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors.Large scale integration of drug-target information reveals poly-pharmacological drug action mechanisms in tumor cell line growth inhibition assays.Alternative scheduling of pulsatile, high dose sunitinib efficiently suppresses tumor growth The pancreatic niche inhibits the effectiveness of sunitinib treatment of pancreatic cancer.Sunitinib-ibuprofen drug interaction affects the pharmacokinetics and tissue distribution of sunitinib to brain, liver, and kidney in male and female mice differently.Tumor-targeted delivery of sunitinib base enhances vaccine therapy for advanced melanoma by remodeling the tumor microenvironment.The Potential Role of Lysosomal Sequestration in Sunitinib Resistance of Renal Cell Cancer.Systematic bias between blinded independent central review and local assessment: literature review and analyses of 76 phase III randomised controlled trials in 45 688 patients with advanced solid tumour Synthesis, Crystal Structure, and Biological Activity ofcis/transAmide Rotomers of (Z)-N′-(2-Oxoindolin-3-ylidene)formohydrazide

P2860

Q28066499-C2D02DB6-0EAD-4DED-860C-F743686D878C Q33411581-B4EDD040-004F-4019-95F7-6634B5613A16 Q35241569-392331C3-FFF1-4CF3-8859-3375FC017D87 Q35434188-6843F926-BE2C-4F14-8AA3-E917619FA9A7 Q36871673-B1E9C1BA-CBCA-492B-AD8E-D2C383F59D7C Q37117596-5E1A2BD4-B5E6-4619-BE44-09A05D1405DB Q37584857-AD2BDBED-F52B-49ED-9DE8-C362F5D9D929 Q38120515-13E76EAB-A60D-4E49-9CCF-ED6FE3FC242C Q38181004-E78F302B-24D8-43E1-9B76-15E9EB7CDAD8 Q38635940-EBCA58AB-7A2B-468A-8092-5C02CCC56BFB Q38679359-4F8A5A3A-045E-488C-B394-77E66D93A389 Q38880510-7D4B29EA-8C16-479E-8254-EE008409EF00 Q38915003-CA1EB035-13E6-43BD-BAF3-0658AC14E027 Q39413595-1BBFDF59-07E5-413E-930D-9A8A019055B9 Q39635470-A06113B1-8F4D-442F-8A33-7CD9C54BD527 Q48159588-4D4FEBC1-0E81-4F09-A440-1EAF819144AC Q51097491-69421C19-FDAE-46F9-85EC-23B23DB5EF03 Q54299389-19FD782B-267A-4A67-A534-ABBD09CB3F61 Q58753938-9B23CA4A-2756-4A14-9C4C-B7AA7B83E1C8 Q59054840-02E90C19-3D87-4E22-A163-116111251113

P2860

FDA approval summary: sunitinib for the treatment of progressive well-differentiated locally advanced or metastatic pancreatic neuroendocrine tumors.

http://www.wikidata.org/entity/Q36182844

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

FDA approval summary: sunitini ...... creatic neuroendocrine tumors.

@ast

FDA approval summary: sunitini ...... creatic neuroendocrine tumors.

@en

type

label

FDA approval summary: sunitini ...... creatic neuroendocrine tumors.

@ast

FDA approval summary: sunitini ...... creatic neuroendocrine tumors.

@en

prefLabel

FDA approval summary: sunitini ...... creatic neuroendocrine tumors.

@ast

FDA approval summary: sunitini ...... creatic neuroendocrine tumors.

@en

P1433

Q36182844-14FE61DC-F4E3-4FF6-8598-115CEB719475

P1476

Q36182844-061EFFEA-AE60-4349-9EDB-0447819D2CD0

P2093

Q36182844-35874CBB-EFCE-4C16-8200-09D9FB4188B3

Q36182844-4680C2B2-00C4-457A-AF9D-16A0F939202F

Q36182844-6B224C02-5AE4-4003-9346-4687E800458C

Q36182844-7E5E15E5-F096-4877-BCA8-DC2413C8A8D8

Q36182844-8CEDE939-92ED-41EF-A554-F31AD21874C5

Q36182844-A40F81F0-752C-4B88-ABAF-FA0984A75AEB

Q36182844-E3AAF41C-647E-4D49-803C-7560EAA77A08

Q36182844-E3F9279E-FD5C-43D4-BE22-1649F79FECF9

P2860

Q36182844-0AD5ADF5-0508-456E-8C64-8904CB453B4B

Q36182844-19DCDB05-1100-4D90-A9CD-F32B409E0CF2

Q36182844-3AE9A6A8-65FD-4D74-9888-5541767BB9F3

Q36182844-46B4BE66-E82E-48E9-B043-3606285D4077

Q36182844-64A9E0B7-B5E7-44A6-9DD8-1FC0597E12C6

Q36182844-78871211-227A-45C7-8320-5E0C6D6D2F8E

Q36182844-8B73F7CA-C92B-472F-AAC6-99CACD95440B

Q36182844-9A37DF7C-02B0-4196-A0A7-8BC68C9AB916

Q36182844-D9091D06-CE5D-4BAA-88AB-31364928A8BB

Q36182844-FC7560F8-1EB6-4487-9C68-C8288315DDB0

P304

Q36182844-69CA341D-2949-487F-93D1-F38C2E6753F6

P31

Q36182844-76B3C692-EC91-485E-85C6-676A95019C6E

P356

Q36182844-CEB71367-E732-4DA4-A5EB-F7382BE59B96

P433

Q36182844-C1296D26-BD56-45CC-BC37-C5D3F3581EAC

P478

Q36182844-D267C629-327B-4CAF-89D5-1E1CBC3C6655

P577

Q36182844-54E568D9-D8BE-43B9-A53B-552FC93FB853

P698

Q36182844-3AC20554-2AEA-4EC4-999B-744E2D6ABD4C

P932

Q36182844-63493B32-2D1C-4FDA-B452-0F79C7CF07FD

P356

THEONCOLOGIST.2012-0044

P1433

P1476

FDA approval summary: sunitini ...... creatic neuroendocrine tumors.

@en

P2093

Anthony Murgo

http://www.w3.org/2001/XMLSchema#string

Gideon M Blumenthal

http://www.w3.org/2001/XMLSchema#string

Jenny J Zhang

http://www.w3.org/2001/XMLSchema#string

Patricia Cortazar

http://www.w3.org/2001/XMLSchema#string

Rajeshwari Sridhara

http://www.w3.org/2001/XMLSchema#string

Richard Pazdur

http://www.w3.org/2001/XMLSchema#string

Robert Justice

http://www.w3.org/2001/XMLSchema#string

Shenghui Tang

http://www.w3.org/2001/XMLSchema#string

P2860

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.

Overall survival as the outcome for randomized clinical trials with effective subsequent therapies

Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense?

One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

Activity of sunitinib in patients with advanced neuroendocrine tumors.

Pancreatic islet cell carcinoma. II. Results of therapy with streptozotocin in 52 patients.

Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas.

A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.

P304

1108-1113

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1634/THEONCOLOGIST.2012-0044

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P577

2012-07-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22836448

http://www.w3.org/2001/XMLSchema#string

P932

3425529

http://www.w3.org/2001/XMLSchema#string